SETD2 and neoplasm: Upon AZD1775 treatment, all seven tumors generated from SETD2-deficient A498 cells regressed from day 3 onward, resulting in a 5.8-fold reduction in tumor size compared to vehicle-treated control animals (tumor size at day 12 = 50.2 ± 4.7 mm3 versus 291.2 ± 40.0 mm3, p < 0.0001) (Figures 5A and 5B).